ILTOO Pharma to attend “The Promise of Interleukin-2 Therapy” meeting

ILTOO Pharma to attend “The Promise of Interleukin-2 Therapy” meeting. ILTOO Pharma SAS to attend the 3rd edition of “The Promise of IL-2 Therapy ” meeting taking place at Sorbonne University in Paris from Sept. 4 to 7, 2024. The company’s CEO, Jeff Lyons, will speak during the “Pharma Perspective” session, addressing the topic “Low Dose Native IL-2: From PoC to Market” on Saturday.

The release as fetched from its publisher. iltoopharma.com ↗